Health · 11 views
No detectable increase in pregnancy risks after GLP-1 exposure around conception, largest review to date finds
Exposure to GLP-1 weight-loss and diabetes drugs around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or babies, according to the largest study of its kind, involving more than 2.1 million…
Summary
Exposure to GLP-1 weight-loss and diabetes drugs around conception is not linked to a clearly detectable increase in adverse outcomes for mothers or babies, according to the largest study of its kind, involving more than 2.1 million pregnancies and led by researchers at City St George's. GLP-1 receptor agonists are a class of medicines used to treat obesity and type 2 diabetes. They include semaglutide, sold under brand names such as Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Plague epidemic risk in Russia low after death of lab technician, WHO saysContinue reading
- Locally grown crops could expand access to childhood malnutrition treatmentContinue reading
- International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseasesContinue reading
- 'Medicare for All' message attracts midterm voters buckling under medical billsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow